美国FDA 指导原则 社区获得性细菌性肺炎正在开发治疗药物 英文原版.pdfVIP

Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) June 2020 Clinical/Antimicrobial Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353 Email: druginfo@ /drugs/guidance-compliance-regulatory-information/guidances-drugs U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) June 2020 Clinical/Antimicrobial TABLE OF CONTENTS I. INTRODUCTION 1 II. BACKGROUND 2 III. DEVELOPMENT PROGRAM 2 A. General Considerations 2 1. Nonclinical Development Considerations 2 2. Drug Development Population 2 3. Efficacy Considerations 2 4. Safety Considerations 3 B. Specific Efficacy Trial Considerations 3 1. Trial Design 3 2. Trial Population 3 3. Entry Criteria 3